Bachem Holding AG
BANB
Classifica tra le azioni
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Prezzo delle azioni
$100.60
Capitalizzazione di mercato
$7.54B
Variazione (1 giorno)
-1.49%
Variazione (1 anno)
49.53%
Paese
CH
Scambia Bachem Holding AG (BANB)
Categoria
Healthcare
Utile per Bachem Holding AG (BANB)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Bachem Holding AG, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Bachem Holding AG dal 2002 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2025 | $197.08M | 31.67% |
| 2024 | $149.68M | 1.35% |
| 2023 | $147.69M | 21.84% |
| 2022 | $121.22M | -15.88% |
| 2021 | $144.11M | 42.32% |
| 2020 | $101.26M | 62.26% |
| 2019 | $62.40M | 12.36% |
| 2018 | $55.54M | 11.92% |
| 2017 | $49.63M | 10.07% |
| 2016 | $45.08M | 20.90% |
| 2015 | $37.29M | 1.92% |
| 2014 | $36.59M | 12.98% |
| 2013 | $32.38M | 52.96% |
| 2012 | $21.17M | 62.51% |
| 2011 | $13.03M | -61.93% |
| 2010 | $34.22M | -23.54% |
| 2009 | $44.76M | -29.32% |
| 2008 | $63.33M | -12.95% |
| 2007 | $72.75M | 49.11% |
| 2006 | $48.79M | 30.20% |
| 2005 | $37.47M | 1.17% |
| 2004 | $37.04M | -5.60% |
| 2003 | $39.24M | 21.47% |
| 2002 | $32.30M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
